Damora Therapeutics, Inc. SEC filings DMRA

Damora Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to Jan 16, 2020. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 20, 2026 (material agreement, change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders May 1, 2026 Dec 31, 2025
10-K Annual report Mar 19, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 30, 2025 Dec 31, 2024
10-K Annual report Mar 19, 2025 Dec 31, 2024
10-K Annual report Mar 8, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 9, 2023 Dec 31, 2022
10-K Annual report Feb 17, 2022 Dec 31, 2021
10-K Annual report Mar 29, 2021 Dec 31, 2020

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DMRA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1800315
Former names
Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.